<DOC>
	<DOCNO>NCT00699712</DOCNO>
	<brief_summary>To access efficacy intravenous ( IV ) administration CD-NP change cardiac output wedge pressure patient stabilize acute heart failure</brief_summary>
	<brief_title>Study Assess Hemodynamic Effects , Safety Tolerability Chimeric Natriuretic Peptide ( CD-NP ) Patients With Stabilized Acute Heart Failure ( AHF )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Key Hospitalization AHF In need hemodynamic monitoring Key Administration intravenous radiographic contrast agent within 7 day prior screen plan IV contrast medium administration 4 day screen acute contrastinduced nephropathy time screen Current plan treatment IV therapy , include diuretic , vasodilator ( include nesiritide ) , vasopressin antagonist , positive inotropic agent vasopressor , mechanical support Current plan ultrafiltration , hemofiltration , dialysis within 7 day screen Significant pulmonary disease Known valvular heart disease Any organ transplant recipient patient currently list transplant admit transplantation . Major surgery within 30 day screen Other major disability disease expect survival less 6 month . Major neurologic event , include cerebrovascular event , 60 day prior screen Clinical diagnosis acute coronary syndrome within 45 day screen Troponin T â‰¥ 3 time upper limit normal screen Significant arrhythmias Acute myocarditis hypertrophic obstructive , restrictive , constrictive cardiomyopathy Liver function abnormality Administration investigational drug implantation investigational device , participation another trial , within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>ADHF</keyword>
	<keyword>AHF</keyword>
	<keyword>HF</keyword>
</DOC>